Premium
Neuroprotection with or without erythropoiesis; sometimes less is more
Author(s) -
Torup L
Publication year - 2007
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0707287
Subject(s) - erythropoietin , neuroprotection , hematocrit , medicine , erythropoiesis , side effect (computer science) , pharmacology , therapeutic window , stroke (engine) , darbepoetin alfa , cytokine , erythropoietin receptor , anemia , programming language , mechanical engineering , computer science , engineering
Erythropoietin (EPO) is a pleiotropic cytokine with a therapeutic potential that goes well beyond the treatment of anaemia. The study by Wang et al (2007b) examined the protective effects of EPO in a rat model of embolic stroke. The efficacy and haematological side effects of EPO were compared to those of a carbamylated EPO variant (CEPO). Treatment with EPO dose‐dependently reduced infarct volume and improved long‐term functional outcome. However, an increase in hematocrit was seen even for doses of EPO that did not offer neuroprotection. These data do not suggest the existence of a therapeutic window between effect and side effect for treatment with EPO. Treatment with CEPO was without haematological side effects. British Journal of Pharmacology (2007) 151 , 1141–1142; doi: 10.1038/sj.bjp.0707287